BioSpace News Archive

Photocure ASA, the Bladder Cancer Company, announces that the Marketing Authorization for Hexvix® in Chile has been granted.

PBS Biotech, a leading provider of cell therapy manufacturing equipment and processes, secures its largest funding round to date to grow its product offerings and capabilities.

Exact Sciences Corp. announced that Japan’s Ministry of Health, Labor and Welfare has approved the Oncotype DX Breast Recurrence Score® Program.

Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease, reported financial results for the second quarter ended June 30, 2021.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, reported financial results and provided a business update for the second quarter ended June 30, 2021.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced its financial results for the three months ended June 30th, 2021 and provided a business update.

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the second quarter ended June 30, 2021 and provided a financial and business update.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the appointment of Michael D. Wyzga as Senior Vice President, Chief Financial Officer.

LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, announced financial results for the second quarter ended June 30, 2021 and recent corporate highlights.

Matinas BioPharma Holdings, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 16/312,047, covering MAT2203, the Company’s oral, LNC formulation of antifungal medicine amphotericin B.